Effect of a Fermented Dairy Food With Probiotics on Mental Performance

NCT ID: NCT05323825

Last Updated: 2023-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-25

Study Completion Date

2023-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single-center, randomized, double-blind, placebo-controlled clinical study with two study groups.

One group will consume a product with functional ingredients and the other group will consume a placebo product. will consume a placebo product.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

When individuals are included in the study they will be randomized in equal proportion to one of the 2 groups of the study. The randomization will be stratified by age taking into account 2 strata (1:1). The first stratum corresponds to an age range of 18 to 40 years and the second stratum to an age range of 41 to 60 years.

The subject must consume the product for 8 weeks and will have a visit 4 weeks later as a follow-up of the study.

At the visits the subject will perform a series of cognitive tests and the intestinal microbiota will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Change

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

The content of the package is 100 g and should be consumed once a day for 8 weeks.

Group Type EXPERIMENTAL

Probiotic

Intervention Type DIETARY_SUPPLEMENT

Fermented milk product containing a probiotic

Control group

The content of the package is 100 g and should be consumed once a day for 8 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Product with identical characteristics to the experimental product.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic

Fermented milk product containing a probiotic

Intervention Type DIETARY_SUPPLEMENT

Placebo

Product with identical characteristics to the experimental product.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 18-60 years.
* Individuals with a diagnosis of mild-moderate stress according to the Cohen's perceived stress scale perceived stress scale (PSS-10).
* Subjects with poor adherence to the Mediterranean diet according to the PREDIMED questionnaire (value below 9 points)\*.
* BMI between 19 and 30 kg/m2.

Exclusion Criteria

* Present chronic and/or acute digestive pathologies that may interfere in the absorption of nutrients (inflammatory intestinal diseases, inflammatory bowel absorption of nutrients (inflammatory intestinal diseases, etc.), etc.)
* Intake of probiotics and/or prebiotics in the four weeks prior to the inclusion in the study.
* Individuals who are on antibiotic treatment or have completed an antibiotic treatment during the 30 days prior to inclusion in the study.
* Vegan diet.
* Being taking any type of supplementation that interacts with cognitive level in the 2 weeks prior to the start of the study.
* Individuals who had taken or were taking any medications or supplementation for stress management, mood, or to induce sleep in the 2 weeks prior to the start of the study.
* A history of allergic hypersensitivity or poor tolerance to any component of the products under study.
* Consumption of 2 or more Standard Drink Units (UBE) daily or 17 weekly in women, or consume 4 or more UBE daily or 28 weekly in men.
* Smoking and non-smoking subjects who have modified their nicotinic habits in the last 3 months.
* Pregnant or lactating women.
* Been participating or have participated in another clinical trial in the 2 months prior to the study to the study.
* Unwillingness or inability to comply with the procedures of the clinical trial.
* Subjects with any diagnosed psychiatric disorder.
* Subjects whose condition makes them ineligible for the study in accordance with the criteria of the investigator.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Católica San Antonio de Murcia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francisco Javier López Román

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fco Javier López Román

Role: PRINCIPAL_INVESTIGATOR

Catholic University of Murcia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Catholic University of Murcia

Murcia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCAMCFE-00026

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.